Physician profile
John Collins
NPI 1003830399
$14,573.93
in general payments reported to CMS, 2019-2025
43 companies · $2,908 in 2025
The $2,908 reported for 2025 was more than what 78% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,272 · 2020: $2,688 · 2021: $1,903 · 2022: $1,783 · 2023: $926 · 2024: $1,094 · 2025: $2,908.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,758 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,758.05 |
| Education | $169.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $2,311.92 | 2019-2025 | |
| Ucb, INC. | $2,098.05 | 2019-2025 | Briviact, Nayzilam, Fintepla |
| Sk Life Science, INC. | $935.07 | 2020-2025 | Xcopri |
| Greenwich Biosciences, INC. | $861.87 | 2019-2021 | |
| Eisai INC. | $826.90 | 2019-2025 | |
| Neurelis, INC. | $661.83 | 2020-2025 | Valtoco |
| Sunovion Pharmaceuticals INC. | $653.12 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $567.91 | 2020-2025 | Acthar |
| Harmony Biosciences LLC | $540.11 | 2020-2025 | Wakix |
| Neurocrine Biosciences, INC. | $500.18 | 2019-2022 | |
| Livanova USA, INC. | $493.58 | 2019-2023 | Vns Therapy Sentiva Model 1000 Generator |
| Lilly USA, LLC | $466.76 | 2019-2025 | Kisunla, Amyvid |
| Supernus Pharmaceuticals, INC. | $436.46 | 2019-2021 | |
| Argenx US, INC. | $351.79 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Teva Pharmaceuticals USA, INC. | $337.08 | 2019-2025 | Austedo Xr, Austedo Xr |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.